🇺🇸 Bendamustine and Rituximab in United States

9 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 9

Most-reported reactions

1. Body Height Decreased — 1 report (11.11%)
2. Drug Ineffective — 1 report (11.11%)
3. Feeling Abnormal — 1 report (11.11%)
4. Heart Rate Increased — 1 report (11.11%)
5. Hypertension — 1 report (11.11%)
6. Incorrect Dose Administered — 1 report (11.11%)
7. Insomnia — 1 report (11.11%)
8. Leukaemia — 1 report (11.11%)
9. Malaise — 1 report (11.11%)

Source database →

Frequently asked questions

Is Bendamustine and Rituximab approved in United States?

Bendamustine and Rituximab does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Bendamustine and Rituximab in United States?

Czech CLL Study Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.